Comparative Analysis of Three Subgroups in Stage II Stomach Cancer

제2기 위암에서 3 Subgroup간의 비교 분석

  • Suh Byung Sun (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Kim Byung Sik (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Kim Yong Ho (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Yook Jung-Whan (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Oh Sung-Tae (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Kim Wan-Soo (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center) ;
  • Park Kun-Choon (Department of Surgery Gastrointestinal Division, University of Ulsan, College of Medicine and Asan Medical Center)
  • 서병선 (울산대학교 의과대학 일반외과학교실) ;
  • 김병식 (울산대학교 의과대학 일반외과학교실) ;
  • 김용호 (울산대학교 의과대학 일반외과학교실) ;
  • 육정환 (울산대학교 의과대학 일반외과학교실) ;
  • 오성태 (울산대학교 의과대학 일반외과학교실) ;
  • 김완수 (울산대학교 의과대학 일반외과학교실) ;
  • 박건춘 (울산대학교 의과대학 일반외과학교실)
  • Published : 2001.03.01

Abstract

Purpose: Three subgroups of stage II stomach cancer (T1N2M0, T2N1M0, T3N0M0) by UICC-TNM staging system show obvious survival difference to each other, which becomes the pitfall of the current staging system. We analyzed the survival and relapse pattern of stage II stomach cancer patients in three subgroups retrospectively to prove the need for change in staging system. Materials and Methods: From July 1989 to December 1995, curative gastric resection was performed in 1,037 patients with gastric adenocarcinoma, and among them 268 patients ($26\%$) were in stage II. The number in each of subgroups (T1N2M0, T2N1M0, and T3N0M0) were 17, 139 and 112 respectively. Survival and relapse pattern were analyzed and median follow up period was 46 months. Results: The 3-year cumulative survival rates of T1N2M0, T2N1M0, and T3N0M0 were $50\%,\;80\%,\;and\;76\%$ respectively (p=0.001). And the 3-year cumulative survival rates of T1N2M0 was comparable to those of 2 subgroups of stage IIIa (T2N2M0, T3N1M0), $47\%\;and\;45\%$ (p>0.05). Peritoneal recurrence was the most frequent in T3N0M0. And hematogenous spread was more frequent in T2N1M0 while nodal spread was more frequent in T1N2M0. Ten out of 17 cases of T1N2M0 died of recurrence. Most of them showed submucosal tumor with depressed lesion and mean tumor size was 3.3 cm. Conclusions: Up-staging of T1N2M0 should be considered because it has the lowest survival rate and the worst prognosis among the three subgroups of Stage II stomach cancer patients. In early gastric cancer patients with high-risk factors (large tumor size, invasion into the submucosal layer, and lymphatic vessel involvement), lymph node dissection and postoperative adjuvant therapy is recommended in an attempt to prevent recurrence in the form of lymph node metastasis.

Keywords